Fig. 1 · Structure

Documents & Downloads

Candesartan

Cat. No. A10175 CAS 139481-59-7

RAAS antagonist

Candesartan is an angiotensin receptor blocker (also called an angiotensin-II receptor antagonist or an AIIRA).

In Stock

Publications for Candesartan

4 publications citing this product

  1. Naomi Fukazawa, .et al. , Pharm Res, 2024, May;41(5):849-861 PMID: 38485855
  2. Hideki Kobara, .et al. , Molecular Medicine Reports, 2020, 22(2) PMID: 32626983
  3. Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851
  4. Toshihide Kashihara, .et al. , J Physiol, 2017, Jul 1; 595(13): 4207-4225 PMID: 28295363

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Candesartan antagonizes human AT1 receptors in transfected CHO cells. Pretreatment reduced maximal angiotensin II signaling, and inhibition persisted after washout. These findings support insurmountable antagonism under the tested conditions; persistent inhibition does not alone establish a unique molecular mechanism. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AT1 receptor 0.26 nM

Cellular Effect

Cell Line Activity Value Description Reference
CHO-K1 IC50 0.69 nM Displacement of [3H]-Angiotensin 2 from human AT1 receptor transfected in CHOK1 cells preincubated for 30 mins with bovine serum albumin followed by radioligand addition by liquid scintillation counting [PMID: 26824643]

Candesartan Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Candesartan from 3 published references. In vitro models include CHO-K1 cells stably expressing human AT1 receptors; CHO-AT1 cells.

Candesartan In Vitro Studies

In CHO-AT1 cells, candesartan inhibited surface [3H]-angiotensin II binding with an IC50 of 0.26 ± 0.05 nM without BSA and 0.69 ± 0.14 nM with 0.1% BSA. Potency depended on assay conditions. [1]

In PC3 cells, 24-hour treatment at 0.5, 5 and 25 µM did not significantly suppress proliferation or viability and reduced apoptosis-associated DNA fragmentation. The mouse tumor result therefore should not be interpreted as evidence of direct PC3 cell killing. [2]

In GIST-T1 cells, 100 µM candesartan reduced the CCK-8 viable-cell signal at 48 hours. The accompanying cell-cycle experiments tested telmisartan, so they do not establish a candesartan-specific mechanism. [3]

AT1 binding and functional antagonism in CHO cells

Cell-based study · CHO-K1 cells stably expressing human AT1 receptors (CHO-AT1) [1]

Candesartan inhibited surface radioligand binding and AngII-induced IP accumulation. Pretreatment suppressed maximal agonist responses, unlike losartan. Wild-type CHO-K1 cells lacked specific binding/AngII responses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Surface binding of 1 nM [3H]-AngII without BSAIC50 0.26 ± 0.05 nM[1]
Surface binding of 1 nM [3H]-AngII with 0.1% BSAIC50 0.69 ± 0.14 nM[1]
IP accumulation induced by 0.1 µM AngII without BSAIC50 0.64 ± 0.03 nM[1]
IP accumulation induced by 0.1 µM AngII with 0.1% BSAIC50 3.43 ± 1.44 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response experiments; Figure 3a: 0.5, 1.5 and 5 nM
Exposure duration
30 min antagonist preincubation; 30 min radioligand binding or 5 min AngII functional challenge
Method
Intact-cell [3H]-AngII binding with acid-releasable surface fraction; radiolabeled inositol-phosphate accumulation at 37°C
Vehicle
DMEM; Table 1 compares absence/presence of 0.1% BSA
Reported limits
Antagonist stock solvent not specified in read Drugs used section.
Methods and source locations

Compound reported in the paper: Candesartan; Compound label in the paper: CV-11974

Reported experimental material; no prodrug dose conversion or lot equivalence.

Table 1 and Figure 3a,d; Methods: Drugs used, IP accumulation and [3H]-Angiotensin II binding; Results: antagonist effects

Surface binding of 1 nM [3H]-AngII without BSA: Nonlinear regression; mean ± s.e.mean, three independent experiments, each in duplicate. — Table 1 (image and footnote)

Surface binding of 1 nM [3H]-AngII with 0.1% BSA: Nonlinear regression; mean ± s.e.mean, three independent experiments, each in duplicate. — Table 1 (image and footnote)

IP accumulation induced by 0.1 µM AngII without BSA: Nonlinear regression; mean ± s.e.mean, three independent experiments, each in duplicate. — Table 1 (image and footnote)

IP accumulation induced by 0.1 µM AngII with 0.1% BSA: Nonlinear regression; mean ± s.e.mean, three independent experiments, each in duplicate. — Table 1 (image and footnote)

Recovery of AT1 signaling after antagonist washout

Cell-based study · CHO-AT1 cells [1]

AngII responses recovered slowly after candesartan removal. Persistent inhibition alone does not prove continued receptor occupancy; the authors retain conformational and rebinding alternatives.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Residual suppression of AngII-induced IP accumulation after 4 h recoveryinhibition 36 ± 3% (0.5 nM pretreatment); 60 ± 3% (5 nM pretreatment)[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.5 or 5 nM candesartan; losartan comparator 300 or 1000 nM
Exposure duration
30 min pretreatment; washout/fresh-medium recovery for up to 5 h; 0.1 µM AngII challenge for 5 min
Method
IP accumulation after antagonist washout, normalized to time-matched medium-only controls
Vehicle
DMEM
Reported limits
Antagonist stock solvent not specified.
Methods and source locations

Compound reported in the paper: Candesartan; Compound label in the paper: CV-11974

Reported experimental material; no prodrug dose conversion or lot equivalence.

Figure 5a,d and associated Results; Methods: IP accumulation/recovery experiments

Residual suppression of AngII-induced IP accumulation after 4 h recovery: Results numerical values; Figure 5 legend: average ± s.e.mean, at least three independent determinations, performed in triplicate. — Figure 5a and Results: washout experiments

PC3 cellular responses include limited antiproliferative activity

Cell-based study · Human PC3 prostate cancer cells [2]

At the concordantly documented 0.5, 5 and 25 µM concentrations, candesartan did not significantly suppress BrdU proliferation or MTT viability and reduced apoptosis-associated DNA fragmentation. These results limit interpretation of tumor-growth inhibition as direct tumor-cell killing.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apoptosis-associated DNA fragments; BrdU incorporation; MTT viabilityqualitative comparison Apoptosis decreased at 0.5, 5 and 25 µM (*P < 0.05); no significant proliferation/viability suppression at these levels[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.5, 5 and 25 µM (concordant methods/figure levels); full figure also includes 50 and 200 µM
Exposure duration
24 h
Method
BrdU incorporation, MTT conversion and histone-associated DNA-fragment ELISA under serum-free conditions
Vehicle
Serum-free DMEM; control DMEM alone
Reported limits
Methods list 10 µM where parts of Figure 2 show 50 µM; do not reconcile these as equivalent. Stock solvent and matched vehicle for these assays not clearly specified; another assay mentions DMSO.
Methods and source locations

Compound reported in the paper: Candesartan; Compound label in the paper: CV-11974

Reported experimental material; no prodrug dose conversion or lot equivalence.

Figure 2A–D; associated Results; Methods: proliferation, viability, apoptosis and migration assays

Apoptosis-associated DNA fragments; BrdU incorporation; MTT viability: Figure 2 shows n = 4 and mean ± S.D.; no exact bar heights inferred. — Figure 2A,C,D and corresponding Results

Candesartan comparison in GIST-T1 cells

Cell-based study · Human GIST-T1 cells [3]

Candesartan at 100 µM reduced the CCK-8 viable-cell signal relative to 0 µM control at 48 h. The cell-cycle and signaling experiments used telmisartan and cannot establish the mechanism of this candesartan result.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CCK-8 viable-cell signal at 48 h versus 0 µMqualitative comparison Lower at 100 µM; **P < 0.01 versus 0 µM[3]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 10 and 100 µM
Exposure duration
48 h treatment in methods; Figure 1 additionally plots 24 h
Method
CCK-8 assay; absorbance at 450 nm, in DMEM with 10% FBS
Vehicle
DMSO stock; methods include 0 µM/vehicle control
Reported limits
Final matched DMSO percentage not specified. CCK-8 is a viable-cell metabolic readout, not direct cell counting. Biological versus technical triplicate distinction is not specified in statistical methods.
Methods and source locations

Compound reported in the paper: Candesartan; Compound label in the paper: candesartan

Reported experimental material; no prodrug dose conversion or lot equivalence.

Figure 1 candesartan panel; Methods: Chemicals and antibodies, Cell culture, Cell proliferation assay, Statistical analyses; first Results subsection

CCK-8 viable-cell signal at 48 h versus 0 µM: Triplicate in-vitro experiments; results mean ± SD. No precise curve values or IC50 inferred. — Figure 1 candesartan panel; Statistical analyses

Candesartan In Vivo Studies

In male nude mice bearing PC3 xenografts, candesartan at 6.5 mg/kg intraperitoneally every 24 hours for 18 days reduced tumor growth and terminal tumor weight relative to saline controls. This is a preclinical model-specific finding. [2]

PC3 xenograft growth in nude mice

Animal study · 8-week-old male athymic nude mice with subcutaneous human PC3 xenografts [2]

Candesartan-treated mice had lower tumor volume at days 18 and 24 after implantation, lower terminal tumor weight and fewer surrounding vessels than saline controls. This model does not establish human anticancer efficacy or direct tumor-cell cytotoxicity.

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Every 24 h
Treatment course
18 days, starting 6 days after PC3 implantation; sacrifice day 24
Vehicle
100 µl of 0.9% saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Candesartan versus saline control
6.5 mg/kg body weight
Daily intraperitoneal 0.9% salineLower tumor volumes at days 18 and 24 (*P < 0.05); lower terminal tumor weight and surrounding vessel count (**P < 0.01); Figure 1: n = 6, mean ± S.D.[2]
Candesartan versus saline control
Model: 8-week-old male athymic nude mice with subcutaneous human PC3 xenografts
Reported limits: No exact plotted values inferred; no human-equivalent dose adopted.
Methods and source locations

Compound reported in the paper: Candesartan; Compound label in the paper: CV-11974

Reported experimental material; no prodrug dose conversion or lot equivalence.

Figure 1A–D; Results: tumor xenograft growth; Methods: In Vivo Nude Mouse Tumor Xenograft Model and Statistical Analysis

Candesartan versus saline control · Figure 1B–D and Methods: In Vivo Nude Mouse Tumor Xenograft Model

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 139481-59-7
Applications RAAS antagonist
Formula C24H20N6O3
Molecular Weight 440.5
Synonyms Blopress; Amias; Ratacand; Atacand
SMILES
CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 79 mg/mL (179.36 mM)
Water Insoluble
Ethanol 1 mg/mL (2.27 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
9 mg/mL
Vehicle
2% DMSO+40% PEG 300+2% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Candesartan Research References

  1. [1] P M L Vanderheyden, F L P Fierens, J P De Backer, et al. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors British Journal of Pharmacology (1999). PMID: 10193788 DOI: 10.1038/sj.bjp.0702398 Source material
  2. [2] Ahmed Alhusban, Ahmad Al-Azayzih, Anna Goc, et al. Clinically Relevant Doses of Candesartan Inhibit Growth of Prostate Tumor Xenografts In Vivo through Modulation of Tumor Angiogenesis The Journal of Pharmacology and Experimental Therapeutics (2014). PMID: 24990940 DOI: 10.1124/jpet.114.216382 Source material
  3. [3] Hideki Kobara, Shintaro Fujihara, Hisakazu Iwama, et al. Antihypertensive drug telmisartan inhibits cell proliferation of gastrointestinal stromal tumor cells in vitro Molecular Medicine Reports (2020). PMID: 32626983 DOI: 10.3892/mmr.2020.11144 Source material

Publications

4 publications citing this product

  1. Naomi Fukazawa, .et al. , Pharm Res, 2024, May;41(5):849-861 PMID: 38485855
  2. Hideki Kobara, .et al. , Molecular Medicine Reports, 2020, 22(2) PMID: 32626983
  3. Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851
  4. Toshihide Kashihara, .et al. , J Physiol, 2017, Jul 1; 595(13): 4207-4225 PMID: 28295363

Added to your cart

View Cart Checkout
Loading...